Market:

The anti-CD138 fused with Interferon (IFN) will both directly kill the malignant cells and will help boost the immune system decreasing the possibility of a relapse. The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021.

Technology:

IFNs are potent anti-cancer agents. In order to treat cancer effectively, high concentrations of IFN at the tumor must be obtained. Qwixel's goal is to concentrate IFN at the tumor site by fusing it to antibodies that recognize CD138, a protein expressed on the surface of myeloma cells.

Advantages:

• Potential to cure disease
• Improved quality of life
• Increased life expectancy

Development Stage:

• Pre-clinical

Patents Issued:

• CD138-Targeted Interferon Demonstrates Potent Apoptotic And Anti-Tumor Activities; US 9,803,021 B2 on 06/04/2015

Select Publications:

• Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma | National Center for Biotechnology Information
• Targeted immunotherapy using anti-CD138-interferon ? fusion proteins and bortezomib results in synergistic protection against multiple myeloma | National Center for Biotechnology Information
• Synergistic Inhibition of Multiple Myeloma Growth by Anti-CD138-Interferon –alpha 14 Fusion Protein and Lenalidomide | Journal of Molecular Immunology

Qwixel Therapeutics merged with Nammi Therapeutics in 2021